close

Enter

Log in using OpenID

Duchenne Muscular Dystrophy (DMD) Treatment Market

embed
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness.
Duchenne Muscular Dystrophy (DMD) Treatment Market
Highlighting Regional Revenue Share Dominance During
2018-2026
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle
degeneration and weakness. DMD is caused due to alteration in gene sequence coding for
dystrophin protein, which is present the muscle. It is a rare muscle disease which majorly
affects males. The symptoms includes intellectual disability, muscle weakness and, difficulty in
walking and breathing. Congestive heart failure, mental impairment, pneumonia or respiratory
failure are some of the complications of this disease. The treatment is available to control or
reduce the signs and symptoms as DMD is not curable. Steroid drugs are used to control the
symptoms of duchenne muscular dystrophy. Stem cell therapy and gene therapy could be used
for treatment of this disease in future.
For In depth Information Get Sample Copy of this Report @
https://www.coherentmarketinsights.com/insight/request-sample/898
Growing investments in the research and development, to find out effective treatment for DMD
is driving the growth of duchenne muscular dystrophy (DMD) treatment market:
According to the reports of Centers for Disease Control and prevention (CDC) 2007, 349 out of
2.37 million males in the United States were reported to be suffering from DMD. Whereas in
2019, 349 new cases of DMD were reported. Increasing incidences of DMD and requirement for
its treatment is driving the growth of duchenne muscular dystrophy treatment market. Various
organizations are involved in spreading awareness and investing in research and development to
find the effective treatment for this disease, which is contributing to the growth of duchenne
muscular dystrophy treatment market. For instance, Muscular Dystrophy Association (MDA), U.S.
invests 75000 USD in research and development to find out the treatment for duchenne
muscular dystrophy and the association funds more than 150 care centers, health care facility
centers, and hospitals across U.S. and other countries. Moreover, other factors, such as constant
research on stem cell therapy, gene therapy, and exon skipping drugs for the treatment of DMD
is expected to propel the growth of DMD treatment market. However, major restraints
hampering the growth of duchenne muscular dystrophy treatment market are, low seeking rate
due to prognosis and late diagnosis of this disease.
Growing patient population in North America and Europe is the factor contributing to the
growth of duchenne muscular dystrophy (DMD) treatment market in these regions:
Regional segmentation of Duchenne muscular dystrophy (DMD) treatment market by Coherent
Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Middle East,
and Africa. North America dominates in the duchenne muscular dystrophy treatment market,
due well-established healthcare facilities in this region. Europe contributes to the growth of
duchenne muscular dystrophy treatment market followed by North America, due to high rate of
affected population in this region. For instance, according to Center for Disease Control and
Prevention (CDC), in North England, 233 out of 1.49 million male patients were reported for
DMD or other muscular dystrophy cases in 2009.
Report includes chapters which deeply display the following deliverable about industry :
• Duchenne Muscular Dystrophy (DMD) Treatment Market Research Objective and Assumption
• Duchenne Muscular Dystrophy (DMD) Treatment Market Purview - Report Description,
Executive Summary, and Coherent Opportunity Map (COM)
• Duchenne Muscular Dystrophy (DMD) Treatment Market Dynamics, Regulations, and Trends
Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New
system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Duchenne Muscular Dystrophy (DMD) Treatment Market, By Regions
• Duchenne Muscular Dystrophy (DMD) Treatment Market Competition by Manufacturers
including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales
Area and Product Type.
• Duchenne Muscular Dystrophy (DMD) Treatment Market Manufacturers Profiles/Analysis
including Company Basic Information, Manufacturing Base and Its Competitors.
• Duchenne Muscular Dystrophy (DMD) Treatment Market Manufacturing Cost Analysis including
Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Key players are involved in the research and development of novel drug therapy for the
treatment of duchenne muscular dystrophy (DMD):
Key players operating duchenne muscular dystrophy (DMD) treatment market includes SUMMIT
Therapeutics Plc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta
Therapeutics, Pfizer Incorporated, Pharmacia & Upjohn LLC, and others. Major industry players
are involved in the research and development of novel drugs for treatment, and strategies such
as collaboration and partnership are adopted by companies to hold the major share in the
duchenne muscular dystrophy (DMD) treatment market. For instance, PTC Therapeutics
International Limited has obtained conditional approval and orphan drug designation in 2014
for Translarna, which is a novel gene therapy for the treatment of duchenne muscular
dystrophy.
Inquire Here Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/898
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars,
called PHASE-XS. This database provides analytical data in addition to the clinical information
of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters,
PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend,
competition, and market potential. For more information or to access this database, kindly click
on the below link or contact at [email protected]
https://www.coherentmarketinsights.com/phase-xs/
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
1/--pages
Report inappropriate content